Unfortunately, this is almost the perfect pump-n-dump scenrio ... a potential mega blockbuster nearing the "big day" ... lots of greed and fear to play upon, and emotions.

I'm a relative "novice" in this space, just enough knowledge of the science and early stage biotech investing to be dangerous to the even lesser informed.

I optimistically and nervously await two things: 1) top line (and eventuall full data), that's the make or break, and 2) financing news to assure we make it to the "that" finish line. Yeah, lots of other milestones, barriers, opportunities, but those seem like the make or break items ..... to me at least?!

Question though? ... How credible are Makalu and Zacks as biotech investment analytical groups? I just ask because I am not that familiar with either of them, but obviously love their past "takes" on RVX ... no idea whether they are "arms length" credible independent consultive investing analysts and information clearing house types ... or groups paid to produce a "good compelling story" based on available facts ..... ?

Boss to Accountant: What do the numbers say?

Accountant back to Boss: Well, boss, what do you want them to say?